Trichostatin A

DRUG2 trials

Sponsors

Vanda Pharmaceuticals

Conditions

Onychomycosis of ToenailRelapsed or Refractory Hematologic Malignancies

Phase 1

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

RecruitingNCT03838926

Vanda PharmaceuticalsRelapsed or Refractory Hematologic Malignancies

Start: 2018-09-27End: 2027-12-01Target: 42Updated: 2026-03-16

Phase 2

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

Active, not recruitingNCT07065773

Vanda PharmaceuticalsOnychomycosis of Toenail

Start: 2025-05-05End: 2026-09-01Target: 50Updated: 2026-02-04

Related Papers

Acetylation and Transcriptomic Activity of Vtr-297 - Results from an Ongoing Phase I Clinical Trial

Blood2024-11-05

Early Transcriptional Activity of Vtr-297 - Results from an Ongoing Phase I Clinical Trial

Blood2022-11-154 citations